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Introduction: There are limited data on the efficacy of early fluid resuscitation with third-generation hydroxyethyl
starch (HES 130) in burn injury. Adverse effects of HES on survival and organ function have been reported.
Methods: In this randomized, controlled, double-blind trial, 48 patients with severe burn injury were assigned to
receive either lactated Ringer’s solution plus 6% HES 130/0.4 in a ratio of 2:1 or lactated Ringer’s solution with no
colloid supplement for the first 72 hours. Primary outcome parameter was the group difference of administered
total fluid from intensive care unit (ICU) admission up to day 3. Secondary outcomes included kidney and lung
injury and failure, length of stay, and mortality.
Results: Three-day totals of administered resuscitation fluid (medians) were 21,190 mL in the lactated Ringer’s
group and 19,535 mL in the HES group (HES: −1,213 mL; P = 0.39). Creatinine levels from day 1 to 3 (HES: +0.4 μmol/L;
95% confidence interval (CI) −18.7 to 19.5; P = 0.97) and urinary outputs from day 1 to 3 (HES: −58 mL; 95% CI −400 to
283; P = 0.90) were not different. Six patients in each group developed acute respiratory distress syndrome (ARDS)
(risk ratio 0.96; 95% CI 0.35 to 2.64; P = 0.95). Length of ICU stay (HES vs. lactated Ringer’s: 28 vs. 24 days; P = 0.80) and
length of hospital stay (31 vs. 29 days; P = 0.57) were similar. Twenty-eight-day mortality was 4 patients in each group
(risk ratio 0.96; 95% CI 0.27 to 4.45; P = 0.95), and in-hospital mortality was 8 in the HES group vs. 5 patients in the
lactated Ringer’s group (hazard ratio 1.86; 95% CI 0.56 to 6.19; P = 0.31).
Conclusions: There was no evidence that early fluid resuscitation with balanced HES 130/0.4 (6%) in addition to
lactated Ringer’s solution would lead to a volume-sparing effect in severe burn injury. Together with the findings that
early renal function, incidence of ARDS, length of stay, and mortality were not negatively influenced by HES in this
setting, balanced HES 130/0.4 (6%) plus lactated Ringer’s solution could not be considered superior to lactated Ringer’s
solution alone.
Trial registration: ClinicalTrials.gov NCT01012648Introduction
There is an ongoing debate on fluid resuscitation in se-
vere burn injury, especially for the first 24 hours after
trauma. Aggressive intravenous fluid therapy according
to the Baxter formula is a mainstay of initial therapy.
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reproduction in any medium, provided the orpost-traumatic phase. Massive systemic inflammation
comparable to severe sepsis leads by the release of numer-
ous mediators such as leukotrienes, prostaglandins, and
particularly histamine, in combination with complement
activation products, to an extensive capillary leak [1,2].
Intravascular molecule and fluid shifts into the extravascu-
lar space cause severe hypovolemia and shock [3]. Changes
in capillary membrane permeability also produce electro-
lytic alteration with intracellular sodium accumulation and
consecutive cellular swelling [4]. Excessive tissue edema,
promoted to a large extent by the leakage of plasma pro-
teins into the extravascular space, normally occurs withintd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lieved to resolve within 8 to 24 hours after trauma, but
data vary [1,5]. In this critical situation of massive inflam-
mation, hypovolemia, and large edema formation, it re-
mains unclear whether a “crystalloid only” therapy or a
combination of crystalloids plus colloids should be used
for volume resuscitation. Expert opinion consisted of
strictly avoiding colloids such as hydroxyethyl starches
(HESs) during the first 24 hours [6]. This restriction was
based on reports from the early 1970s expressing the fear
of overloading the interstitial compartment with colloids
in the early stage of trauma due to increased capillary
leakage, thus leading to impaired wound healing after sur-
gical treatment [7,8]. Although in 1998 the Cochrane
Injuries Group presented a relative risk of death after al-
bumin administration of 2.4 in a meta-analysis [9], human
albumin is still used in burn to reduce the fluid require-
ments for resuscitation [10,11] and tissue edema. With
the same intention, different types of HES are frequently
administered in burn injury, although safety and efficacy
of HES products for fluid resuscitation are not fully evalu-
ated and are intensely disputed especially during the last
few years. However, we just recently have demonstrated in
a prospective interventional open-label study that hyper-
oncotic HES 200/0.5 (10%) might be associated with fatal
outcome when used for early fluid resuscitation in severe
burn injury [12]. A recent randomized controlled trial
assigned 26 burn patients either to Hartmann’s solution
plus HES 200/0.6 (6%) or to Hartmann’s solution only.
The HES-supplemented fluid therapy led to significantly
less fluid application than the Hartmann’s regimen and
showed reduced interstitial edema [13]. The least side
effects on kidney function and coagulation are attrib-
uted to the third-generation HESs such as HES 130/0.4
(6%), but data on early fluid resuscitation in major burn
with these modern starches are limited. Therefore in this
current randomized controlled trial we addressed the
question of whether modern HES 130/0.4 (6%) adminis-
tered within the first 24 hours after severe burn injury and





This study was an investigator-initiated, prospective, ran-
domized, controlled, double-blind single-center trial. The
study protocol was approved by the local ethical commit-
tee (KEK Kantonale Ethik Kommission [Cantonal Ethical
Committee] 4, Canton Zurich) and the Swiss Agency for
Therapeutic Products (Swissmedic). Power calculation
and planning of the statistical analysis were done at the
Horten Centre for patient-oriented research at University
Hospital of Zurich. Reporting of the study was doneaccording to the CONSORT (Consolidated Standards of
Reporting Trials) guidelines.
Participants
All adults (age ≥16 years) who had 2nd- or 3rd-degree
acute burn injury and more than 15% of body surface
area burned and who were admitted to the University
Hospital of Zurich burn unit between 1 November 2009
and 31 January 2013 were eligible for the study. All ne-
cessary written informed consent (deferred consent, if
necessary, according to Swiss law HMG § 55 and § 56)
was obtained from the patient or their legal surrogate
within 24 hours after inclusion. In the case of written
consent of the legal surrogate, all survivors gave written
informed consent after recovery, which is in line with
the local ethics committee regulations. Patients were
excluded when they were expected to succumb within
the next 24 to 36 hours (that is, burn victims with whole
body burn trauma) or in situations of palliative care,
pregnancy, lack of informed consent, known allergy to
HES, contraindications for balanced 6% HES 130/0.4, in-
tracerebral bleeding, acute renal failure, severe hyperna-
tremia and other severe electrolyte disorders, severe von
Willebrand Syndrome, and acute liver failure.
Study setting
The study was performed in a tertiary burn unit at the
University Hospital of Zurich, Switzerland. The center is
the larger of the two national burn units in Switzerland
and runs six acute care beds. About 80 severe burn vic-
tims are admitted to the university hospital per year.
Interventions
The primary study medication was balanced 6% HES
130/0.4. After patient enrollment and randomization,
fluid resuscitation was done as follows. Each patient first
received two bags of unblinded lactated Ringer’s solution
(500 mL each bag), followed by one bag (500 mL) of
blinded study solution, the latter being either again lac-
tated Ringer’s solution or balanced 6% HES 130/0.4.
After each bag of study solution, all patients again re-
ceived two bags of unblinded lactated Ringer’s solution,
before a next bag of study solution from the blinded box
was infused. This fluid regimen alternating unblinded
lactated Ringer’s fluid with blinded study solution en-
sured an overall ratio of crystalloids versus colloids of
2:1 in the HES patients. The patients not receiving HES
but blinded lactated Ringer’s study solution instead were
exposed solely to crystalloids during the entire course of
the study. Fluid resuscitation was guided by predefined
target variables as listed in Figure 1. Accordingly,
fluid administration was increased or decreased until
target variables were reached. The administration of
additional albumin or any other colloid was excluded in
MAP < 60 mmHg
Continue fluid resuscitation, when :
ScvO2 < 65%









• If the points 2 to 4 are fulfilled, but not point 1,
start vasopressor therapy.
• If the points 1 to 4 are fulfilled, reduce fluid resuscitation
Figure 1 Hct, hematocrit; MAP, mean arterial pressure; ScvO2,
central venous oxygen saturation; UO, urinary output.
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tered as continuous infusions via peristaltic pumps. Infu-
sion rate (mL/h) was continuously adjusted to the
actual patient fluid needs. Except for volume resusci-
tation, there was no difference in patient care, including
cardiovascular monitoring, pharmacologic and respiratory
support, nutrition, and surgical treatment of burn
wounds.
Outcome measures
Primary outcome was the group difference of adminis-
tered resuscitation fluid within the first 72 hours after
admission. Secondary endpoints were creatinine level at
day 1 and the difference over day 1 to 3, urine output at
day 1 and the difference over day 1 to 3, incidence of
acute respiratory distress syndrome (ARDS) [14] during
hospitalization, length of stay in the intensive care unit
(ICU), length of stay in the hospital, in-hospital mortal-
ity, and 28-day mortality. Collected baseline characteris-
tics were age, sex, systolic and diastolic blood pressure,
heart rate, body weight, body height, percentage of burn,
and the amount of pre-hospital administered fluids.
A post hoc analysis was performed for 90-day mortality
and incidence of renal replacement therapy during hos-
pital stay.
Sample size
We based our sample size calculations on the primary
outcome, which is the total volume of fluids given within
the first 72 hours of treatment. We used data from our
previous study with HES 200/0.5 [12] to estimate the
average total volume of fluids given within the first 72hours of treatment with crystalloids (25 L with crystal-
loid and 18 L with HES) and to estimate its variability
(standard deviation of around 12 and 7 L, respectively).
A sample size of 24 patients in each group allowed a dif-
ference of 25%, respectively, in total volume of fluids
given within the first 72 hours of treatment between the
groups with a power of 80% at a significance level of 5%
(two-sided).Blinding and randomization
A third party not involved in the conduction (KAZ,
Kantonsapotheke, Zurich) performed randomization and
prepared the study solution, either balanced 6% HES
130/0.4 or lactated Ringer’s solution, by sealing the identi-
cal 500-mL bags in black plastic foil concealing the prod-
uct label and content. Thus, there was no possibility to
recognize the fluid used. Bags were packed into boxes.
Three boxes of the same content labelled in consecu-
tive order were assigned to each patient, one box for each
24-hour period up to 72 hours. For randomization,
minimization was used with stratification for age (< or ≥50
years). Since minimization does not have a pre-specified
randomization list, concealment of random allocation
was ensured. Thus, all patients were randomly assigned
double-blind either to the lactated Ringer’s plus balanced
6% HES 130/0.4 group or to the lactated Ringer’s-only
group, and study medication was assigned to the patients.
To make sure that there was no overload of 6% HES 130/
0.4 study medication, the maximum amount (for HES ac-
cording to the manufacturer’s manual 50 mL per kg body
weight per 24 hours) was calculated on the basis of the es-
timated body weight at study enrollment. A body weight
of 80 kg, for example, led to 4,000 mL of study solution,
which resulted in eight bags of 500 mL each of blinded so-
lution. Not more than that was brought to the patient.
Statistical methods
We included all patients in the analysis according to the
group they were randomly assigned to. To compare the
outcomes between the two groups, we used linear re-
gression analysis for continuous outcomes (for example,
fluids), logistic regression for binary outcomes (for ex-
ample, ARDS), and Cox proportional hazard regression for
in-hospital mortality, always with group allocation as
an independent variable. To compare the total volume of
fluids given within the first three days after randomization,
creatinine values, and urinary output over the first 72
hours, we used a random effects model that took the auto-
correlated structure of repeated measurements (measure-
ment on first, second, and third day) into consideration
(xtreg command of STATA). All analyses were conducted
by using STATA (STATA for Windows, version 10.2; Stata
Corp., College Station, TX, USA).





Age, years 49 (22, 69) 47 (26, 61)
Sex, male 17 (73.9%) 17 (77.2%)
Systolic blood pressure, mm Hg 109 (93, 130) 123 (104, 150)
Diastolic blood pressure, mm Hg 60 (55, 65) 68 (59, 76)
Heart rate, beats/min 83 (70, 95) 86 (75, 95)
Weight, kg 75 (70, 83) 80 (70, 80)
Height, cm 175 (170, 180) 176 (170, 180)
Burned TBSA, % 31 (21, 47) 32 (20, 50)
Data are represented as median (25th and 75th percentiles) or median
(percentage). None of the differences between the two groups was significant
(P >0.05). Two patients were randomly assigned but were excluded because
they did not fulfill inclusion criteria, and one patient was not excluded
formally but was not in analyses, because of a lack of data. HES, hydroxyethyl
starch; TBSA, total body surface area.
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Participants
From 1 November 2009 through 31 January 2013, 159
patients were assessed for inclusion in the study, and
111 patients were not eligible. From the enrolled 48
patients, 24 patients were assigned to receive lactated
Ringer’s solution plus balanced 6% HES 130/0.4 (HES
group) and 24 to receive lactated Ringer’s solution (lac-
tated Ringer’s group). Two patients had to be excluded
from the study because they retrospectively did not ful-
fill inclusion criteria. (One primarily included patient
with a negative pregnancy test had to be excluded second-
arily because a revised pregnancy test was positive shortly
thereafter. One patient was initially assessed as having a
20% deep burned area but showed less than 15% intraop-
eratively). One patient was lost for analysis in the lactated
Ringer’s group because of early discharge within less than
72 hours from the ICU. This patient was formally not ex-
cluded, but no study data were available for incorpor-
ation in the statistics. Participant flow is shown in
Figure 2. Baseline characteristics were well balanced
between groups (Table 1).
Fluid therapy
During the pre-hospital phase, the lactated Ringer’s group
received a median of 1,800 mL and the HES group 2,000Assessed for e
Analysed  (n=23)
Excluded (did not fulfill inclusion criteria) (n=1)
Allocated to HES 130/0.4 (n=24)
Random
Figure 2 Study flow diagram.mL of fluid (difference not significant); no colloids were
administered. Calculated fluid requirement for the first 24
hours based on the Baxter formula was not different be-
tween the two groups (lactated Ringer’s group: 8,520 ver-
sus HES: 9,000 mL). The median 3-day total of effectively
administered fluid was 21,190 mL in the lactated Ringer’s
group versus 19,535 mL in the HES group. A median
amount of 5,650 mL of HES was administered in theligibility (n=159)
Excluded  (n=111)
Not meeting inclusion criteria (n=110)
Declined to participate (n=0)
Other reasons (n=1 )
Excluded (did not fulfill inclusion criteria) (n=1)
Allocated to Lactated Ringer’s (n=24)
Analysed  (n=22)
Lost to follow-up (early discharge from ICU), 
not excluded, but no data available (n=1)
ized (n=48)
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tated Ringer’s group (Table 2).
Outcomes
Regarding the primary endpoint, there was a group
difference in fluids given over the first 72 hours of −1,213
mL in the HES group, which was not statistically sig-
nificant (95% confidence interval (CI) −3,975 to 1,549;
P = 0.39). With regard to secondary outcomes, there was
no difference over the first 72 hours in creatinine levels
(+0.4 μmol/L; 95% CI −18.7 to 19.5; P = 0.97) or in urinary
output (−58 mL; 95% CI −400 to 283; p = 0.90). The inci-
dence of ARDS was 6 patients in each group (risk ratio
0.96; 95% CI 0.35 to 2.64; P = 0.95), and again there was
no difference in length of ICU stay and hospital stay (28
vs. 24 days; P = 0.80 and 31 vs. 29 days; P = 0.57), respect-
ively. Twenty-eight-day mortality was 4 patients in each
group (risk ratio 0.96; 95% CI 0.27 to 4.45; P = 0.95), and
in-hospital mortality was 8 in the HES group versus 5 in
the lactated Ringer’s group (hazard ratio 1.86; 95% CI 0.56
to 6.19; P = 0.31) (Table 3).
The results of the post hoc analysis of 90-day mor-
tality and incidence of renal replacement therapy showed
no difference between the groups. Data are depicted in
Table 4.
Discussion
In this randomized controlled trial, no fluid saving effect
was detected by the use of balanced 6% HES 130/0.4 as
compared with lactated Ringer’s solution alone in pa-
tients with severe burn injury. Furthermore, early renal
function as determined by serum creatinine levels, devel-
opment of ARDS, length of ICU and hospital stay, and
in-hospital and 28-day mortality were not different be-





Pre-hospital crystalloids, mL 2,000 (1,000, 2,500) 1,800 (1,000, 3,600)
Pre-hospital colloids, mL 0 (0, 0) 0 (0, 0)
Baxter formula, mL 9,000 (5,880, 13,536) 8,520 (7,920, 18,080)
Total fluids
at day 1, mL
10,050 (6,700, 16,800) 11,575 (9,300, 19,770)
Total fluids at day 2, mL 5,500 (3,750, 8,825) 5,025 (3,180, 9,300)
Total fluids at day 3, mL 3,340 (2,060, 7,000) 4,150 (1,640, 6,100)
Total fluids at
days 1–3, mL
19,535 (13,820, 29,770) 21,190 (14,760, 33,960)
Total crystalloids
at days 1–3, mL
13,200 (10,075, 19,020) 21,190 (14,760, 33,960)
Total colloids
at days 1–3, mL
5,650 (3,745, 9,000) 0 (0, 0)
Data are represented as median (25th and 75th percentiles). HES,
hydroxyethyl starch.In severe burn injury with massive systemic inflammation
comparable to severe sepsis, aggressive fluid resuscitation
to maintain hemodynamic stability and stable kidney func-
tion is pivotal. The most widely accepted formula to esti-
mate fluid requirements in burns is the Baxter formula,
which, however, rather underestimates the volume needed
in about half of the patients [15-17]. The downside of sig-
nificant fluid load in burned patients might be accentuated
edema formation and thus impaired wound healing after
surgical treatment. Hence, a reduction of fluid load, espe-
cially during the first 24 to 48 hours, when the most resus-
citation volume is needed, appears to be desirable in order
to improve surgical outcome.
The role of HES in various clinical settings remains
controversial. A possible volume-sparing effect, assigned
to colloids in general, is the main indication for its wide-
spread use, although the extent of fluid load reduction
may be overestimated. There are only few data about the
use of HES in patients with burn injury. In a recent ran-
domized controlled trial in burned patients, Vlachou and
colleagues [13] showed a clear volume-sparing effect and
furthermore reduced edema formation with HES 200/0.6
(6%) supplementation. However, as reported by our
group, older-generation HES such as the hyperoncotic
HES 200/0.6 (10%) might be associated with a higher in-
cidence of renal failure and higher overall mortality in
severe burn injury [12]. One explanation could be re-
lated to the fact that only about 33% to 66% of the
administered hyperoncotic HES is excreted in the urine
in the first 24 hours after infusion [18]. Thus, the
remaining HES molecules, which are still in high con-
centration, may circulate for a long time and a substan-
tial proportion might accumulate in various tissues,
including kidney. Hyperoncotic HES deposition was
demonstrated in dogs by histopathology in intravascular
and interstitial spaces of various organs, including prox-
imal renal tubular cells, thus possibly inducing renal fail-
ure [19]. There are also many case studies describing
acute deterioration of pre-existing renal impairment
after the administration of hyperoncotic HES [20,21].
Very limited data are available on modern third-
generation HESs such as HES 130 in burns. Only one
small randomized open-label study reported more favor-
able parameters related to the extent of tissue edema
and a reduced mortality with HES 130/0.4 [13]. With re-
gard to kidney function, James and colleagues [22] just
recently demonstrated in penetrating trauma patients re-
suscitated with HES 130/0.4 a better lactate clearance
and less acute kidney injury than in patients treated with
saline. Furthermore, in an observational retrospective
study in 363 ICU patients, Boussekey and colleagues
[23] showed no difference in acute kidney injury after
the use of HES 130/0.4 as compared with crystalloids. These
findings, not necessarily connecting the administration of







Total volume at days 1–3, mL −1,213 (95% CI −3,975 to 1,549) 0.39
Secondary outcomes
Creatinine at day 1, μmol/L 77 (66, 99) 74 (55, 90)
Creatinine at days 1–3, μmol/L 0.4 (95% CI −18.7 to 19.5) 0.97
Urinary output at day 1, mL/d 1,360 (1,020, 1,770) 1,430 (970, 2,225)
Urinary output at days 1–3, mL −58 (95% CI −400 to 283) 0.90
Incidence of ARDS 6 (26.1%) 6 (27.3%)
Risk ratio for ARDS with HES 0.96 (95% CI 0.35 to 2.64) 0.95
28-day mortality 4 (17.4%) 4 (18.2%)
Risk ratio for 28-day mortality with HES 0.96 (95% CI 0.27 to 4.45) 0.95
In hospital mortality 8 (34.8%) 5 (22.7%)
Hazard ratio for in-hospital death with HES 1.86 (95% CI 0.56 to 6.19) 0.31
Length of stay in ICU, days 28 (10, 58) 24 (11, 49) 0.80
Length of stay in hospital, days 31 (18, 58) 29 (14, 61) 0.57
Data are represented as median (25th and 75th percentiles) or number of patients (percentage) or risk ratio (confidence interval) or hazard ratio (confidence
intervals, or CIs). For total volume, creatinine, and urinary output over days 1–3, absolute values with original units (confidence intervals) are depicted. ARDS,
acute respiratory distress syndrome; HES, hydroxyethyl starch; ICU, intensive care unit.
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showing no increasing creatinine levels over the first 3 days
of fluid resuscitation with HES 130. However, it has to be
mentioned that in our study HES 130 was co-infused to-
gether with lactated Ringer’s solution in a ratio of 2:1, which
might protect the kidney from acute deterioration and fail-
ure. In large contrast, several recent trials and analyses not
focusing on burn injury have drawn different conclusions
with regard to kidney failure. Although an improvement of
sublingual microcirculation after resuscitation with HES
130/0.4 versus saline was reported [24], septic patients re-
ceiving HES 130 were more likely to develop acute kidney
injury, requiring renal replacement therapy, and to be at in-
creased risk of death after 90 days [25]. This is in line with
the findings in a large multicenter trial in which it was
shown in 7,000 patients that the application of HES 130/0.4
resulted in more adverse events and more renal replacement
therapies as compared with patients receiving 0.9%
saline for fluid resuscitation [26]. When these recent
large studies and meta-analyses are taken together, HESTable 4 Post hoc analysis 90-day mortality and need for rena
Outcome (post hoc analysis) HES (n = 23) Lacta
90-day mortality 8 (34.8%)
Risk ratio for 90-day mortality with HES
Need for RRT 6 (26.1%)
Risk ratio for need of RRT with HES
Data are represented as number of patients (percentage) or risk ratio (confidence inproducts, including HES 130 preparations, might be
associated with increased mortality and acute kidney
injury in ICU patients [27-32]. Whether these data can
ultimately be translated to burn injury needs further
investigation.
The current study has several limitations: firstly, the
application of resuscitation fluids was algorithm-based
and conducted by different members of our ICU staff.
Nevertheless, over two years of study duration, this ef-
fect has probably been levelled out over time. Secondly,
the used volume resuscitation algorithm was very
traditional and did not include any hemodynamic
measurement tools such as pulmonary artery catheter or
pulse-induced contour cardiac output. Only clinical signs
and various hemodynamic and surrogate parameters (mean
arterial pressure, central venous oxygen saturation, urinary
output, and hematocrit) were used to guide volume
therapy. The reason for this simplified approach comes
on the one hand from our clinical experience with fluid
therapy in burned patients suggesting that this approachl replacement therapy
ted Ringer’s (n = 22) Difference P value
6 (27.3%)
1.27 (95% CI 0.51 to 3.26) 0.59
6 (27.3%)
0.96 (95% CI 0.35 to 2.64) 0.95
terval, or CI). HES, hydroxyethyl starch; RRT, renal replacement therapy.
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evidence for better fluid therapy by the use of advanced
hemodynamic guidance tools. Our data show that esti-
mated fluid requirements for the first 24 hours (calcu-
lated with the Baxter formula) are comparable to the
effectively infused amount of resuscitation fluid in both
the HES and the crystalloid group. And as known from the
literature, the Baxter formula rather underestimates
the necessary amount of infusion fluid [15-17], which was
the case in our study as well. Thirdly, power calculation
was done to detect a potential volume-sparing effect but
not to determine differences in mortality, organ failure,
and length of stay. The latter are secondary endpoints, for
which the study is underpowered due to the relatively
small sample size. Therefore, differences in mortality,
organ failure, and length of stay have to be interpreted
with caution.
The strength of the study is its randomized, double-
blinded, and controlled design, making the findings reli-
able and of clinical relevance. An implication for further
research would be the initiation of randomized controlled
trials with large sample sizes to strengthen the current evi-
dence of a missing volume-sparing effect of modern HESs
in burn injury. With regard to safety concerns that have
arisen after the latest meta-analysis reporting a significant
risk for mortality and acute kidney injury in various pa-
tient groups [28], further studies should specifically ad-
dress this issue in burned patients.
Conclusions
This randomized, controlled, double-blind study did not
provide any evidence that early fluid resuscitation with
balanced HES 130/0.4 (6%) as an add-on fluid to lactated
Ringer’s solution during the first 72 hours after burn
injury would lead to a volume-sparing effect. Together
with the findings that early renal function, incidence
of ARDS, length of stay, and mortality were not nega-
tively influenced by HES in this setting, balanced HES
130/0.4 (6%) plus lactated Ringer’s solution could not
be considered superior to lactated Ringer’s solution
alone.
Key messages
 All patients received more resuscitation fluid than
Baxter formula suggested.
 The use of balanced 6% hydroxyethyl starch (HES)
130/0.4 did not result in reduced fluid requirement
in severe burn victims.
 There is no advantage to using 6% HES 130/0.4 in
severe burn injury.
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